Phenotypic analysis of mice expressing exclusively apolipoprotein B48 or apolipoprotein B100 - PubMed (original) (raw)
Phenotypic analysis of mice expressing exclusively apolipoprotein B48 or apolipoprotein B100
R V Farese Jr et al. Proc Natl Acad Sci U S A. 1996.
Abstract
Apolipoprotein (apo)-B is found in two forms in mammals: apo-B100, which is made in the liver and the yolk sac, and apo-B48, a truncated protein made in the intestine. To provide models for understanding the physiologic purpose for the two forms of apo-B, we used targeted mutagenesis of the apo-B gene to generate mice that synthesize exclusively apo-B48 (apo-B48-only mice) and mice that synthesize exclusively apo-B100 (apo-B100-only mice). Both the apo-B48-only mice and apo-B100-only mice developed normally, were healthy, and were fertile. Thus, apo-B48 synthesis was sufficient for normal embryonic development, and the synthesis of apo-B100 in the intestines of adult mice caused no readily apparent adverse effects on intestinal function or nutrition. Compared with wild-type mice fed a chow diet, the levels of low density lipoprotein (LDL)-cholesterol and very low density lipoprotein- and LDL-triacylglycerols were lower in apo-B48-only mice and higher in the apo-B100-only mice. In the setting of apo-E-deficiency, the apo-B100-only mutation lowered cholesterol levels, consistent with the fact that apo-B100-lipoproteins can be cleared from the plasma via the LDL receptor, whereas apo-B48-lipoproteins lacking apo-E cannot. The apo-B48-only and apo-B100-only mice should prove to be valuable models for experiments designed to understand the purpose for the two forms of apo-B in mammalian metabolism.
Similar articles
- Lipoprotein clearance mechanisms in LDL receptor-deficient "Apo-B48-only" and "Apo-B100-only" mice.
Véniant MM, Zlot CH, Walzem RL, Pierotti V, Driscoll R, Dichek D, Herz J, Young SG. Véniant MM, et al. J Clin Invest. 1998 Oct 15;102(8):1559-68. doi: 10.1172/JCI4164. J Clin Invest. 1998. PMID: 9788969 Free PMC article. - Susceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B48 or apolipoprotein B100.
Véniant MM, Pierotti V, Newland D, Cham CM, Sanan DA, Walzem RL, Young SG. Véniant MM, et al. J Clin Invest. 1997 Jul 1;100(1):180-8. doi: 10.1172/JCI119511. J Clin Invest. 1997. PMID: 9202070 Free PMC article. - Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet.
Purcell-Huynh DA, Farese RV Jr, Johnson DF, Flynn LM, Pierotti V, Newland DL, Linton MF, Sanan DA, Young SG. Purcell-Huynh DA, et al. J Clin Invest. 1995 May;95(5):2246-57. doi: 10.1172/JCI117915. J Clin Invest. 1995. PMID: 7738190 Free PMC article. - Apolipoprotein B mRNA editing: a key controlling element targeting fats to proper tissue.
Davidson NO. Davidson NO. Ann Med. 1993 Dec;25(6):539-43. Ann Med. 1993. PMID: 8292303 Review. - Using genetically modified mice to study apolipoprotein B.
Young SG. Young SG. J Atheroscler Thromb. 1996;3(2):62-74. doi: 10.5551/jat1994.3.62. J Atheroscler Thromb. 1996. PMID: 9226457 Review.
Cited by
- Translatome profiling reveals Itih4 as a novel smooth muscle cell-specific gene in atherosclerosis.
Ravindran A, Holappa L, Niskanen H, Skovorodkin I, Kaisto S, Beter M, Kiema M, Selvarajan I, Nurminen V, Aavik E, Aherrahrou R, Pasonen-Seppänen S, Fortino V, Laakkonen JP, Ylä-Herttuala S, Vainio S, Örd T, Kaikkonen MU. Ravindran A, et al. Cardiovasc Res. 2024 Jul 2;120(8):869-882. doi: 10.1093/cvr/cvae028. Cardiovasc Res. 2024. PMID: 38289873 Free PMC article. - Dissecting the polygenic basis of atherosclerosis via disease-associated cell state signatures.
Örd T, Lönnberg T, Nurminen V, Ravindran A, Niskanen H, Kiema M, Õunap K, Maria M, Moreau PR, Mishra PP, Palani S, Virta J, Liljenbäck H, Aavik E, Roivainen A, Ylä-Herttuala S, Laakkonen JP, Lehtimäki T, Kaikkonen MU. Örd T, et al. Am J Hum Genet. 2023 May 4;110(5):722-740. doi: 10.1016/j.ajhg.2023.03.013. Epub 2023 Apr 14. Am J Hum Genet. 2023. PMID: 37060905 Free PMC article. - Potential therapeutic targets for age-related macular degeneration: The nuclear option.
Choudhary M, Malek G. Choudhary M, et al. Prog Retin Eye Res. 2023 May;94:101130. doi: 10.1016/j.preteyeres.2022.101130. Epub 2022 Oct 8. Prog Retin Eye Res. 2023. PMID: 36220751 Free PMC article. Review. - Development and validation of a method to deliver vitamin A to macrophages.
Acharya P, Black M, Bressner G, Amengual J. Acharya P, et al. Methods Enzymol. 2022;674:363-389. doi: 10.1016/bs.mie.2022.04.008. Epub 2022 May 12. Methods Enzymol. 2022. PMID: 36008013 Free PMC article. - Characterization and identification of measurable endpoints in a mouse model featuring age-related retinal pathologies: a platform to test therapies.
Choudhary M, Tayyari F, Handa JT, Malek G. Choudhary M, et al. Lab Invest. 2022 Oct;102(10):1132-1142. doi: 10.1038/s41374-022-00795-7. Epub 2022 May 19. Lab Invest. 2022. PMID: 35589984 Free PMC article.
References
- J Clin Invest. 1984 Mar;73(3):816-23 - PubMed
- J Lipid Res. 1996 Feb;37(2):347-60 - PubMed
- J Biol Chem. 1986 Mar 5;261(7):2995-8 - PubMed
- Anal Biochem. 1986 Aug 15;157(1):106-16 - PubMed
- Cell. 1990 Sep 21;62(6):1073-85 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous